FGH BioTech Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $2.08M
Latest Deal Amount
  • Investors
  • 2

FGH BioTech General Information

Description

Developer of small molecule drugs designed to treat metabolic disorders and cancer. The company's drugs target the master regulatory switch for fat production, known as sterol regulatory element-binding proteins (SREBP), enabling physicians to treat obesity, non-alcoholic fatty liver disease, type II diabetes, and lipid disorders.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 414 Thamer Circle
  • Houston, TX 77024
  • United States
+1 (713) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

FGH BioTech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 19-May-2018 $2.08M 00.000 Completed Generating Revenue
3. Early Stage VC (Series A) 18-Mar-2016 000 000 0000 Completed Generating Revenue
2. Angel (individual) 06-Nov-2015 Cancelled Generating Revenue
1. Grant 01-Jan-2014 $1.84M Completed Generating Revenue
To view FGH BioTech’s complete valuation and funding history, request access »

FGH BioTech Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 000,000 00.000000 000 000 00 000 00.000
To view FGH BioTech’s complete cap table history, request access »

FGH BioTech Patents

FGH BioTech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3510027-A1 Di-substituted pyrazole compounds for the treatment of diseases Pending 07-Sep-2016 0000000000
JP-2019530742-A Disubstituted pyrazole compounds for the treatment of diseases Pending 07-Sep-2016 0000000000
AU-2017323521-A1 Di-substituted pyrazole compounds for the treatment of diseases Granted 07-Sep-2016 0000000000
US-20190194167-A1 Di-substituted pyrazole compounds for the treatment of diseases Pending 07-Sep-2016 0000000000 0
CA-3036195-A1 Di-substituted pyrazole compounds for the treatment of diseases Pending 07-Sep-2016 C07D401/14
To view FGH BioTech’s complete patent history, request access »

FGH BioTech Executive Team (4)

Name Title Board Seat Contact Info
Salih Wakil Ph.D Co-Founder, President & Chairman
Joe Wakil President & Board Member
Lufti Abu-Elheiga Ph.D Co-Founder & Vice President of Research and Development
Motonari Uesugi Ph.D Co-Founder
To view FGH BioTech’s complete executive team members history, request access »

FGH BioTech Board Members (3)

Name Representing Role Since
Adam Kuspa FGH BioTech Board Member 000 0000
Joe Wakil FGH BioTech President & Board Member 000 0000
Salih Wakil Ph.D FGH BioTech Co-Founder, President & Chairman 000 0000
To view FGH BioTech’s complete board members history, request access »

FGH BioTech Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BCM Technologies Venture Capital Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
To view FGH BioTech’s complete investors history, request access »